NCT07078695
A Trial of SHR-1139 in Healthy Volunteers
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 11 words
- Primary completion date changed from estimate of Sep 30, 2026 to Nov 9, 2026
- Study completion pushed from Sep 30, 2026 to Jan 30, 2027
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Aug 26, 2025 to Aug 19, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
PK profile of SHR-1139 after a single administration
Timeframe: Start of Treatment to end of study (Day 253)
PK profile of SHR-1139 after a single administration:
Timeframe: Start of Treatment to end of study (Day 253)
Immunogenicity profile of SHR-1139 after a single dose administration
Timeframe: Day 253
Secondary (1)
Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events
Arms and interventions
SHR-1139 dose level 1Experimental
Single dose of SHR-1139 given subcutaneously (dose level 1)
SHR-1139 dose level 2Experimental
Single dose of SHR-1139 given subcutaneously (dose level 2)
SHR-1139 dose level 3Experimental
Single dose of SHR-1139 given intravenously (dose level 3)
Drugs: SHR-1139 Injection
Sites
1 site in 1 country
- LinearPerth, Western Australia, Australia